Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

E2031

Sigma-Aldrich

Eliprodil

≥98% (HPLC), powder

Synonym(s):

α-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol, SL 820715

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H23ClFNO
CAS Number:
119431-25-3
Molecular Weight:
347.85
MDL number:
MFCD00866651
UNSPSC Code:
12352200
PubChem Substance ID:
24277709
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear
H2O: insoluble

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

OC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3

InChI

1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2

InChI key

GGUSQTSTQSHJAH-UHFFFAOYSA-N

Gene Information

human ... GRIN2B(2904)
rat ... Adra1a(29412)

Biochem/physiol Actions

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

O A Dravolina et al.
Pharmacology, biochemistry, and behavior, 65(4), 611-620 (2000-04-15)
Current perspectives on the clinical use of NMDA receptor antagonists infer repeated administration schedules for the management of different pathological states. The development of tolerance and cross-tolerance between different NMDA receptor antagonists may be an important factor contributing to the
P J Missel et al.
Pharmaceutical development and technology, 11(1), 87-91 (2006-03-21)
Measurement of drug release of a sparingly soluble drug by conventional methods proceeds very slowly without the aid of surfactants. Two preliminary automated methods were developed that increase sensitivity and accelerate such studies by working at very small reservoir volumes.
P Wlaź et al.
Neuropharmacology, 38(2), 243-251 (1999-04-28)
The discovery that glutamate's activity at the N-methyl-D-aspartate (NMDA) receptor is positively modulated by glycine and polyamines has led to a new pharmacological strategy that NMDA receptor-mediated events could be antagonized indirectly at the strychnine-insensitive glycine co-agonist site (glycine(B) receptor)
N A Sharif et al.
The British journal of ophthalmology, 83(2), 236-240 (1999-07-09)
This study characterised the pharmacology of [3H]-ifenprodil binding to the polyamine binding sites (PBS) on the N-methyl-D-aspartate (NMDA) receptor channel complex on human retinas. These data were correlated with the known neuroprotective effects of ifenprodil and eliprodil. Specific binding of
J E Nash et al.
Experimental neurology, 155(1), 42-48 (1999-01-27)
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service